newsfilter
← Latest News
Business Wire·

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer's Disease at CTAD 2021

Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer's disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will participate at the upcoming 14th Clinical Trials on Alzhei